Clinical Trial Update: CHinese ischEmic Stroke Beyond 4.5 Hours With TeNecteplase Under Optimized Non-Contrast CT Selection [Phase 3]

View source ↗

Summary

Phase 3 trial assessing extended-window use of tenecteplase for acute ischemic stroke beyond 4.5 hours with optimized non-contrast CT selection; currently recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stroke

Drugs mentioned

• TNKASE (tenecteplase)

Snippet

Sponsor: Huashan Hospital | Conditions: Acute Ischemic Stroke | Phase 3 | Status: RECRUITING